Jazz Pharmaceuticals (JAZZ): Cutting PT ~30% - Mizuho

Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) but cut her price target to $127.00 from $185.00.

The estimate and PT cuts reflect a 3Q:16 miss and disclosure of a potentially disappointing Xyrem life-cycle extension product. The analyst sharpened her pencil and became more conservative with her Xyrem assumptions and overall outlook. The new PT of $127 is based on lower pricing, higher discounts, and assumed competitive entry in 2022.

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $106.19 yesterday.

You May Also Be Interested In

• HDFC Asset Management Co Ltd (HDFCAMC:IN) PT Raised to INR3,250 at JPMorgan
• HSBC Downgrades Hermes International (RMS:FP) (HESAY) to Hold
• Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink